GlassScriptPhysician profile
Edwin L Price
NPI 1124129911
$2,459.90
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,062 · 2022: $1,151 · 2023: $180 · 2024: $66.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $433.39 | 2021-2024 | |
| Abbott Laboratories | $364.51 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $205.39 | 2021-2023 | Rybelsus, Ozempic |
| Amgen INC. | $157.70 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $147.92 | 2021-2022 | |
| Astellas Pharma US INC | $123.16 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.93 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.23 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $91.25 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.60 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.40 | 2021-2023 | Trulance, Xifaxan |
| Merck Sharp & Dohme LLC | $56.29 | 2021-2023 | Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $53.18 | 2022 | |
| Antares Pharma, INC. | $52.86 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $52.12 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $50.79 | 2022 | |
| Amarin Pharma, INC. | $47.13 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.39 | 2021-2022 | |
| Sanofi Pasteur INC. | $28.79 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $23.15 | 2021 | |
| Eisai INC. | $22.70 | 2021 | |
| Bausch Health US, LLC | $19.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.22 | 2021 | |
| Horizon Therapeutics Plc | $17.88 | 2022 | |
| Glaxosmithkline, LLC. | $17.33 | 2023 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $15.04 | 2022 | |
| Pfizer INC. | $14.33 | 2023 | |
| Mylan Specialty L.P. | $13.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.72 | 2021 | |
| Daiichi Sankyo INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.